Generating a Non-Integrating Human Induced Pluripotent Stem Cell Bank from Urine-Derived Cells

Yanting Xue1,2,3, Xiujuan Cai1,3, Linli Wang1,3, Baojian Liao1,3, Hui Zhang1,3, Yongli Shan1,3, Qianyu Chen1,3, Tiancheng Zhou1,3, Xirui Li1,3, Jundi Hou1,2,3, Shubin Chen1,3, Rongping Luo1,3, Dajiang Qin1,3, Duanning Pei1,2,3, Guangjin Pan1,2,3+

Abstract

Induced pluripotent stem cell (iPSC) holds great potential for applications in regenerative medicine, drug discovery, and disease modeling. We describe here a practical method to generate human iPSCs from urine-derived cells (UCs) under feeder-free, virus-free, serum-free condition and without oncogene c-MYC. We showed that this approach could be applied in a large population with different genetic backgrounds. UCs are easily accessible and exhibit high reprogramming efficiency, offering advantages over other cell types used for the purpose of iPSC generation. Using the approach described in this study, we have generated 93 iPSC lines from 20 donors with diverse genetic backgrounds. The non-viral iPSC cell bank with these cell lines provides a valuable resource for iPSC research, facilitating future applications of human iPSCs.

Introduction

Human somatic cells can be reprogrammed back into pluripotent state as induced pluripotent stem cells that can undergo unlimited self-renewal while maintaining the potential to differentiate into all three germ layers. Human iPSCs hold great potential to be used for personalized regenerative medicine, drug discovery and disease modeling, for circumventing ethical issues [1]. To date, human iPSCs cells have been successfully generated from different tissue sources, such as skin fibroblasts [2,3], extra-embryonic tissues [4] and blood cells [5], although the reprogramming efficiencies varied much for different cell types. Moreover, the virus-based approach used in most of these reports raised the safety concerns, which hampered their further applications. To enable the application of iPSC technology, it is essential to develop and optimize a practical approach to generate iPSCs under a feeder-free, virus-free and serum-free condition. To date, several non-viral approaches have been reported to generate mouse and human iPSCs, by using adeno-virus [6], plasmids [7], purified proteins [8,9], synthesized mRNA [10,11,12]. However, these approaches remain inefficient or laborious. We and others had previously described that epithelia-like cells could be isolated from human urine and could be further reprogrammed into iPSCs with high efficiency by using virus-based approach [13,14,15,16]. Human UCs can be conveniently obtained through non-invasive method, thus representing an ideal cell source for iPSC generation. Here, in this report, we had examined whether isolation of UCs to generate iPSCs can be applied in a large population with different genetic background. We firstly describe an efficient method to reprogram human UCs without using virus, serum, feeder and without oncogene c-MYC. By using this method, we have been generating a non-viral human iPSC cell bank from donors in different ages and various genetic and disease backgrounds. Our non-integrating human iPSC cell bank, enables comprehensive study of iPSC cells from different origins, and also provides a valuable source for disease modeling and mechanical analysis.

Results and Discussion

We have easily recruited people for urine donation because urine collection is non-invasive and routinely carried out for clinical diagnosis (55 out of 60 surveyed people accepted to donate urine sample. Fig. S1A). With consent form signed by the donors, we have collected and established 46 UC lines (Table 1 and Table 2) from 50–200 ml middle stream of the micturition. These donors include people with different ages (from 2 to 73 years old) and various disease genetic backgrounds. For all the donated urine samples examined so far, we could successfully isolate and expand epithelia cells from more than 90% of them, demonstrating that our approach for isolating UCs can be universally applied for most people (Fig. 1A). For these 46 established UC lines, 19 of them...
were collected from healthy people and 27 from patients that were diagnosed clinically with different diseases, such as hereditary blood disorders (hemophilia and β-thalassemia), autoimmune diseases, nervous neurological disorders (amyotrophic lateral sclerosis ALS, and myotonic dystrophy et al.). For the genetic diseases, we confirmed the mutations of β-thalassemia in 2 donors (Fig. S1B). Potential mutations of Alport’s syndrome and ALS were not detected in the samples (5 genes known to cause ALS and 7 mutation sites of COL5A4 causing Alport’s syndrome were listed in Table S1 and Table S2) because they are complicated genetic diseases. We also analyzed the proliferation percentage of UCs by EdU assay (Fig. 1B). Most of these UC lines proliferated well and could be expanded for more than 5 passages. In some cases (2 out of 46), we had to recollect the urine samples in order to get enough cells for further culture.

To obtain non-integrating iPS cells from these UC lines, we chose episomal system to deliver the reprogramming factors. Episome, which derived from EBV EBNA/OriP system to enable the replication of transfected plasmid in eukaryotic cells, had been used in iPS cell generation from neonatal fibroblasts and CD34+ hematopoietic progenitor cells in different laboratories [17,18,19]. Except specific donor cell type human adult adipose tissue-derived stem cells (AdSC) [20], most of these reports included oncogene c-MYC as reprogramming factor, raising risks in maintaining genomic stability during iPS generation [19,20]. In addition, some of them used serum and mouse feeder cells for reprogramming.
Therefore, we sought to reprogram human UCs through episomal system without using serum, feeders and c-MYC. To test the episomal system in UCs, we transfected an episomal vector encoding EGFP into these cells through electroporation. We showed that EGFP expression efficiency was remarkable, about 35% cells were positive for EGFP expression (Fig. 1C). Next, we found that UCs could survive and grow in serum-free media for iPS generation with UCs as illustrated in Figure 1E. Because involvement of oncogene c-MYC during reprogramming might increase the risk of genomic toxicity [23], we tried to omit it by using OCT4, SOX2, SV40T, KLF4 (OSTK, encoded by pEP4EO2SET2K). However, we failed to obtain stable iPS colonies from UCs or skin fibroblasts (Fig. 1F), indicating that the OSTK four factor were insufficient for non-integrating iPS cell generation under serum-free conditions. We and several other groups had shown that miR-302-367 cluster could greatly enhance somatic reprogramming efficiency [24,25,26]. In addition, we found that mice chimeras with genome integrations of miR-302-367 cluster and their offspring are tumor-free for over 2 years. Thus, miR-302-367 cluster might be less genomically toxic and even suppress tumorigenicity of human pluripotent stem cells [27] and be a better choice for non-integrating iPS cell generation than c-MYC. We then constructed an episomal vector expressing human miR-302-367 cluster (named pCEP4-miR302-367 cluster, Fig. S2A and S2B) and simultaneously transfected it into UCs with OSTK through electroporation. The transfected UCs were then cultured on matrigel-coated plate and in totally defined and serum free medium (mTesR1 or E8) for reprogramming. Around 20 days after electroporation, we could observe human ES like colonies. The cells exhibited traditional human ES/iPS morphology with a high nuclear to cytoplasmic ratio (Fig. 1G). However, the reprogramming efficiencies varied a lot for different donors. For 5×10^4 cells we routinely used to start reprogramming, the number of human ES like colonies varied between 0 and 72 for different individuals. The representative reprogramming efficiencies of three different donors were shown in Figure 1H and efficiencies of other donors were listed in Table 1. Most of the colonies with human ES like morphology could be picked and expanded successfully. To the contrary, when we applied the same reprogramming factors combination on skin fibroblasts, we did observe morphology change, but failed to obtain alkaline phosphatase (AP) positive iPSC cell colonies under same culture condition (Fig. 1F). These data indicated that UCs were much easier to be reprogrammed than skin fibroblasts. This is consistent to our previous finding that the fibroblasts not the UCs need to go through a mesenchymal-to-epithelial transition (MET) process, which might hamper their iPS cell generation [28]. We further confirmed this by showing that UCs expressed higher level of markers or accelerators of MET, such as E-CADHERIN, CLAUDIN, OCCLUDIN and miR-200c, miR-302b, but lower level of repressors for MET, like TWIST (Fig. S2C). Moreover, we failed to generate human iPS cells from UCs with the episomal miR-302-367 cluster vector alone, consistent with a previous report [26]. To date, through the approaches described above, we have successfully generated UC derived iPSCs (UiPSCs) from 20 donors with different genetic and disease backgrounds (Table 1), demonstrating that it is a universal strategy, albeit with efficiencies varied for different donors. It is not surprise because the reprogramming efficiency variations had been well documented in mice [29,30]. As for the donors, we haven’t found that the

Table 1. List of UiPSCs generated from UCs.

| Cell code | Genetic backgrounds | Age (y) | M/F* | Efficiency | Colonies picked | Karyotype** | qPCR | Non-integrating | IF/FACS | Teratoma |
|-----------|---------------------|--------|------|------------|----------------|------------|------|----------------|---------|---------|
| UC-001    | Alpoarts disease    | 45     | M    | 0.0026%   | 8              | 4/8        | 3/8  | 3/8            | 5/8     | 2/8     |
| UC-002    | Hemophilia B        | 2      | M    | 0.0013%   | 15             | 3/15       | 2/15 | 3/15           | 2/15    | ND      |
| UC-003    | Healthy             | 25     | M    | ND        | 3              | 2/3        | 3/3  | 3/3            | 2/3     | ND      |
| UC-004    | Hemophilia A        | 10     | M    | 0.0006%   | 4              | 1/4        | 1/4  | 1/4            | 1/4     | ND      |
| UC-005    | Hemophilia A        | 2.5    | M    | 0.0024%   | 7              | 2/7        | 2/7  | 2/7            | 2/7     | ND      |
| UC-006    | Hemophilia A        | 21     | M    | ND        | 6              | 1/6        | 1/6  | 1/6            | 1/6     | ND      |
| UC-007    | Hemophilia A        | 22     | M    | ND        | 2              | 1/2        | 1/2  | 1/2            | 1/2     | ND      |
| UC-008    | Healthy             | 27     | M    | 0.0001%   | 1              | 1/1        | 1/1  | 1/1            | 1/1     | 1/1     |
| UC-009    | β-thalassemia       | 3      | M    | ND        | 8              | 2/8        | 2/8  | 2/8            | 2/8     | ND      |
| UC-010    | Healthy             | 60     | M    | 0.0002%   | 2              | 1/2        | 1/2  | 1/2            | 1/2     | ND      |
| UC-011    | Hemophilia A        | 12     | M    | ND        | 5              | 5/5        | 1/5  | 1/5            | 1/5     | 2/5     |
| UC-012    | Healthy             | 25     | M    | 0.0003%   | 5              | 2/5        | 2/5  | 2/5            | 2/5     | 1/5     |
| UC-013    | Healthy             | 26     | M    | 0.001%    | 3              | 1/3        | 1/3  | 1/3            | 1/3     | ND      |
| UC-014    | CMT                 | 42     | M    | 0.013%   | 4              | 2/4        | 2/4  | 2/4            | 2/4     | ND      |
| UC-015    | Healthy             | 25     | M    | 0.0007%   | 4              | 3/4        | 3/4  | 4/4            | 2/4     | 1/4     |
| UC-027    | Healthy             | 26     | F    | ND        | 2              | 1/8        | 2/8  | 2/8            | 2/8     | ND      |
| UC-040    | β-thalassemia       | 12     | M    | ND        | 2              | 2/2        | ND   | ND            | ND      | ND      |
| UC-041    | β-thalassemia(carrier) | 28     | F    | 0.015%   | 6              | 2/6        | 2/6  | 2/6            | 1/6     | 1/6     |
| UC-044    | ALS                 | 54     | M    | ND        | 6              | ND         | ND   | ND            | ND      | ND      |
| UC-046    | Healthy             | 70     | M    | 0.007%   | 4              | 1/4        | ND   | ND            | ND      | ND      |

doi:10.1371/journal.pone.0070573.t001
individuals with certain disease exhibited particularly different reprogramming efficiencies (listed in Table 1). The generation of iPSCs from UCs listed in Table 2 is underway. For each individual UC line, we usually picked and expanded at least 2 colonies for further characterization. Our standard iPSC cell characterization was illustrated in Figure 2. The expanded colonies that passed the characterization including karyotyping, non-integrating and pluripotency will be deposited in the bank. Taking iPSCs generated from UC-012 for example, firstly, by using genomic PCR that could specifically amplify transgenes used for reprogramming, we confirmed that the stably expanded iPSC colonies no longer harbored the exogenous reprogramming factors (Fig. 2A), and kept the normal karyotype determined by G-band analysis (Fig. 2B). We further demonstrated that endogenous pluripotent genes such as \textit{OCT4}, \textit{SOX2} and \textit{NANOG} were fully activated and were comparable to human embryonic stem cells (Fig. 2C–2E). Further by analyzing DNA methylation, we showed that the proximal promoters of \textit{OCT4} and \textit{NANOG} were de-methylated (Fig. 2F). We performed embryoid body (EB) formation assay to demonstrate that the iPSCs cells could form typical EBs that expressed genes of three germ layer tissues (Fig. 2H). The information of characterization on other iPSC cell lines was listed in Table 1 and Figure S3.

In all, we describe here a feasible and highly practical process to generate iPSCs from UCs in a totally defined condition that is feeder-free, virus-free and without using \textit{c-MYC}. We have now generated 93 iPSC cell lines from 20 individuals with various backgrounds (Table 1). Generation of non-viral and feeder-free iPSC cell bank is an important step towards the further applications. Employing UCs for non-viral iPSC cell generation offers several advantages over other cell types such as skin fibroblasts and blood cells. Firstly, it is a totally non-invasive and easy process that is applicable for virtually any candidate to donate tissue, particularly for children and those patients with certain diseases such as hemophilia. Secondly, UCs exhibit the epithelial phenotype and are much easier to be reprogrammed to iPSCs than mesenchymal skin fibroblasts, by circumventing the MET process. This is particularly important for using non-viral approaches to generate iPSCs, as the efficiencies of most reported non-viral approaches are very low. Indeed, we failed to obtain stably expanded iPSCs from skin fibroblasts using our approaches described above. Lastly, the whole process is serum-free and feeder-free which makes it feasible to generate clinical non-viral human iPSC cells under current good manufacture practice (cGMP) conditions in future.

One important safety concern for iPSC cells is the genomic stability [31,32,33,34,35], which has been reported in extended passaging of human ESCs [36]. However, Geti et al. reported recently that iPSCs process appeared to generate little or no CNVs, even using vial approaches [33]. Further studies will be needed to analyze the genomic and epigenomic stabilities in detail on the iPSC cell lines generated from different genetic backgrounds. The non-integrating iPSC cell bank described here contains dozens of iPSC cell lines from different individuals but generated in the same laboratory and the same condition, thus provides a valuable source for comprehensive comparative analysis. The bank is expanding rapidly and also a good resource for disease modeling and future applications in regenerative medicine.

We have previously reported that UCs can be reprogrammed into neural progenitor cells (NPCs) through the same combination of vectors described in this report plus a cocktail of small molecules to inhibit signaling pathways [37]. It had been shown that the external signaling pathways such as SMAD and GSK3B signaling are important in shaping the neural stem cell fate [38,39]. As for the urine cell reprogramming, we reasoned that the signaling inhibitors present in the medium played critical roles in determining whether the cells become NPCs or iPSCs. Our future work is to dissect the molecular mechanisms of the reprogramming process in the presence of those signaling inhibitors.

### Materials and Methods

#### Ethical Statement

The individuals in this manuscript have signed written informed consent for donating human UCs for stem cell generation. The experiments involving human subject and animal research had been reviewed and approved by IRB at GIBH (NO. 2010012). We have previously reported that UCs can be reprogrammed into neural progenitor cells (NPCs) through the same combination of vectors described in this report plus a cocktail of small molecules to inhibit signaling pathways [37]. It had been shown that the external signaling pathways such as SMAD and GSK3B signaling are important in shaping the neural stem cell fate [38,39]. As for the urine cell reprogramming, we reasoned that the signaling inhibitors present in the medium played critical roles in determining whether the cells become NPCs or iPSCs. Our future work is to dissect the molecular mechanisms of the reprogramming process in the presence of those signaling inhibitors.

#### Collection and Expansion of UCs

UCs were collected and cultured as described previously [13]. The cells passaged less than 4 times were used for iPSC cell generation.

### Table 1. List of other UC lines.

| Cell code | Genetic backgrounds | M/F | Age(year) |
|-----------|---------------------|-----|-----------|
| UC-016    | Hemophilia A        | M   | 12        |
| UC-017    | Hemophilia A        | M   | 7         |
| UC-018    | Hemophilia A        | M   | 2.5       |
| UC-019    | Hemophilia A        | M   | 6         |
| UC-020    | Hemophilia A        | M   | 2.5       |
| UC-021    | Hemophilia A        | M   | 50        |
| UC-022    | Hemophilia A        | M   | 10        |
| UC-023    | Hemophilia A        | M   | 23        |
| UC-024    | Healthy             | F   | 22        |
| UC-025    | Healthy             | F   | 25        |
| UC-026    | Healthy             | M   | 25        |
| UC-028    | Healthy             | M   | 25        |
| UC-029    | Healthy             | M   | 25        |
| UC-030    | Healthy             | M   | 31        |
| UC-031    | Healthy             | M   | 31        |
| UC-032    | Healthy             | M   | 29        |
| UC-033    | Amyotrophic lateral sclerosis | M | 73 |
| UC-034    | Healthy             | M   | 69        |
| UC-035    | Systemic lupus erythematosus | F | 5 |
| UC-036    | β-thalassemia       | M   | 5         |
| UC-037    | Aport’s syndrome    | F   | 39        |
| UC-038    | Amyotrophic lateral sclerosis | M | 57 |
| UC-039    | Parkinson Disease   | M   |           |
| UC-042    | Healthy             | M   | 23        |
| UC-043    | Healthy             | M   | 29        |
| UC-045    | β-thalassemia(carrier) | F | 54 |

*M: male; F: female.

**Additional notes:**
- UCs were collected and cultured as described previously [13]. The cells passaged less than 4 times were used for iPSC cell generation.
- iPSCs process appeared to generate little or no CNVs, even using vial approaches [33]. Further studies will be needed to analyze the genomic and epigenomic stabilities in detail on the iPSC cell lines generated from different genetic backgrounds.
- The non-integrating iPSC cell bank described here contains dozens of iPSC cell lines from different individuals but generated in the same laboratory and the same condition, thus provides a valuable source for comprehensive comparative analysis.
- The bank is expanding rapidly and also a good resource for disease modeling and future applications in regenerative medicine.
All patients with genetic diseases were diagnosed by clinical standards in our collaborated hospital. Sanger sequencing was used to confirm the potential mutations.

EdU (5-ethyl-2'-deoxyuridine) Imaging and Cell Proliferation Analysis

EdU labeling and cell proliferation analysis was performed using Click-iT® EdU Imaging Kit with Alexa Fluor® (Life technologies), following the instructions of the manufacturer. 1.5×10^5 human UCs at passage 4 were seeded per well in 24-well plates. EdU was added to cells 12 h after seeding and pulsed for 2.5 h. The EdU-treated cells were fixed and followed by the highly-specific click reaction. A Leica DMI6000B microscope (Leica Microsystems GmbH, Germany) was used for observation and photographing. Samples were analyzed in triplicate.

iPS Cell Generation

Briefly, 5×10^5–1×10^6 UCs at early passages were individualized by trypsin treatment (0.25% Trypsin/0.5 mM EDTA, Gibco) and electroporated with indicated episomal plasmids using Amaxa® Basic Nucleofector® Kit for primary mammalian Epithelial cells, program T-020 (LONZA), or cells could be resuspended in PBS solution and electroporated using Gene Pulser MXcell Electroporation System (BIO-RAD). The electroporated UCs were seeded onto matrigel (BD) pre-coated P6 wells. In each
electroporation, 3.5 μg pEP4EO2SET2K (contains OCT4, SOX2, STF4LTL and LIN7) and 2.5 μg pCEP4-M2L (contains c-MYC and LN230) or pCEP4-mir-302-367 cluster (contains miR-302b, c, a, d and miR-367) were used. Defined medium mTeSR1 (STEM-CELL) or E8 medium (DMEM/F12 (Hyclone) +2% ITS (Gibco)+Vc (70 μg/ml), Sigma)+bFGF (100 ng/ml, Invitrogen)+TaqB (2 ng/ml, PeproTech) [22] was changed during daily generation.

The iPS cells colonies were picked at around Day 20–Day 30 and cultured in mTeSR1 or E8 on matrigel. The culture medium was changed daily. The iPS cells were passaged with dispase (Gibco, 1 mg/ml in DMEM/F12) for the initial 2–5 passages depending on the cells and then passaged with 0.5 mM EDTA (Sigma, dissolved in PBS (Gibco)).

iPS Cells Characterization

PCR analysis of exogenous reprogramming factors and episomal backbone integration, immunofluorescence microscopy (OCT-3/4 Antibody, Santa Cruz Biotechnology se-5279; Human Nanog Affinity Purified Polyclonal Ab, R&D AF1997; Anti-SSEA4 antibody, Abcam AB16287; Anti-TRA-1-60, Millipore MAB 4360), AP staining, karyotyping, bisulfate sequencing and teratoma formation were performed as we described previously [13,37]. The primers used for cloning, PCR analysis, qPCR and bisulfate sequencing were listed in Table S3. Total RNA was extracted using Trizol (invitrogen), and reverse transcribed by oligo dT or specific primers. qPCR was performed in triplicate with CFX96 machine (BIO-RAD) and SYBR Green Premix EX Taq™ Kit (Takara) following the instructions by the manufacturer.

Flow Cytometry Analysis

About 1×10⁶ iPS cells were used for each staining. iPS cells were trypsinized and fixed with 1% paraformaldehyde dissolved in PBS for 10 min at 37°C. The cells were then washed with FACS buffer (PBS contains 2% fetal bovine serum, FBS) and resuspended in 90% ethanol for permeabilization by incubating 30 min on ice. After washing, cells were sequentially incubated with primary and secondary antibody for 30 min at 37°C. Control samples were stained with isotype-matched control antibodies. The iPS cells were washed and resuspended in FACS buffer and then processed for analysis on FACS Calibur (BD).

Embryonic Body (EB) Formation and in vitro Differentiation

iPS colonies on matrigel coated plate were incubated with collagenase IV (Gibco) for about 30 min at 37°C till the colonies were completely dissociated. The colonies were washed with DMEM/F12 and resuspended in EB medium (DMEM/F12+20% Knockout serum replacement, KSR (Gibco)+1% L-GluMax (Gibco)+1% NEAA (Gibco)+1% β-mercaptoethanol (Gibco)). The colonies were cultured in suspension for 4 days then transferred onto matrigel coated plate and cultured for 4 days more.

Statistical Analyses

Data were shown in mean. Error bars indicated standard deviation of the mean. P values were calculated by one-way ANOVA and Bonferroni post-hoc test, or student’s t test by Origin.

Author Declaration

Cell lines and samples related in this report are available upon request for noncommercial use.

Supporting Information

Figure S1 A. Anonymous survey results of willingness for donating samples. B. Mutation of HBB in UC-041 (β-thalassemia carrier) and UiPSC-041 C1P8 by sequencing. C. Mutations of HBB in UC-009 (β-thalassemia) and UiPSC-009 C3P15 by sequencing. (TIF)

Figure S2 A. Map of the plasmid pCEP4-hsa-miR-302-367 cluster used in the study. B. qPCR for miR-302b expression of cells transfected with plasmid pCEP4-hsa-miR-302-367 cluster. Cells transfected with pCEP4-EGFP were used as control. Values are referred to 10⁶ copies of RN6. C. qPCR for MET related genes expression of UCs relative to skin fibroblasts. (TIF)

Figure S3 Characterization of two typical non-integrating iPS cell lines generated from UC-015 and UC-041 respectively. A. Non-integrating analysis of episomal DNA in the iPS cell lines generated from UC-015. B. G-band analysis of UiPSC-015 C1P12. C. Immunofluorescence for human ES markers of UiPSC-015 C1P16. D. Methylation status of OCT4 and MVOG promoters in UC-015 and UiPSC-015 C1P11. E. HE-staining of the teratomas from UiPSC-015 C1P16. F. Non-integrating analysis of episomal DNA in the iPS cell lines generated from UC-041. G. G-band analysis of UiPSC-041 C1P9. H. Immunofluorescence for human ES markers of UiPSC-041 C1P12. I. Methylation status of OCT4 and MVOG promoters in UC-041 and UiPSC-041 C1P8. J. HE-staining of the teratomas from UiPSC-041 C1P10. (TIF)

Table S1 Mutation detection of UC-001 (Alport’s syndrome). (DOCX)

Table S2 Mutation detection of UC-044 (ALS). (DOCX)

Table S3 Primer list. (DOCX)

Acknowledgments

We are grateful to Dr. Juan Du for critical reading of the manuscript.

Author Contributions

Conceived and designed the experiments: YX DP GP. Performed the experiments: YX XC LW BL HZ YS QC TZ XL JH SC RL DQ. Analyzed the data: YX BL GP. Contributed reagents/materials/analysis tools: YX BL GP. Wrote the paper: YX BL GP.

References

1. Yamakawa S (2009) A Fresh Look at iPS Cells. Cell 137: 13–17.
2. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. Cell 131: 861–872.
3. Yu, JY, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917–1920.
4. Cai J, Li W, Su H, Qin D, Yang J, et al. (2010) Generation of Human Induced Pluripotent Stem Cells from Umbilical Cord Matrix and Aminiotic Membrane Mesenchymal Cells. J Biol Chem 285: 11227–11234.

5. Loh Y-H, Agarwal S, Park I-H, Urbach A, Hou H, et al. (2009) Generation of induced pluripotent stem cells from human blood. Blood 113: 3476–3479.

6. Stadtfeld M, Nagaya M, Uitkahl J, Weir G, Hochedlinger K (2008) Induced Pluripotent Stem Cells Generated Without Viral Integration. Science 322: 945–949.

7. Chinn A, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S (2008) Generation of Mouse Induced Pluripotent Stem Cells Without Viral Vectors. Science 322: 949–953.

8. Kim D, Kim C-H, Moon J-H, Chung Y-G, Chang M-Y, et al. (2009) Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins. Cell Stem Cell 4: 472–476.

9. Zhou H, Wu S, Joo JY, Zhu S, Han DW, et al. (2009) Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins. Cell Stem Cell 4: 381–384.

10. Warren L, Manos PD, Aifedi T, Loh Y-H, Li H, et al. (2010) Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNA. Cell Stem Cell 7: 618–630.

11. Plews JR, Li J, Jones M, Moore HD, Mason C, et al. (2010) Activation of Pluripotency Genes in Human Fibroblast Cells by a Novel mRNA Based Approach. PLoS ONE 5: e14397.

12. Warren L, Ni Y, Wang J, Guo XR (2012) Feeder-Free Derivation of Human Induced Pluripotent Stem Cells with Messenger RNA. Scientific Reports 2: 657.

13. Zhou T, Benda C, Dunzinger S, Huang Y, Li X, et al. (2011) Generation of Induced Pluripotent Stem Cells from Urine. J Am Soc Nephrol 22: 1221–1229.

14. Zhou JM, Wang X, Zhang SL, Gu YJ, Yu L, et al. (2013) Generation and Characterization of Human Cryptorchid-Specific Induced Pluripotent Stem Cells from Urine. STEM CELLS DEV 22: 717–725.

15. Chen Y, Luo R, Xu Y, Cai X, Li W, et al. (2013) Generation of systemic lupus erythematosus-specific induced pluripotent stem cells from urine. Rheumatology International. [Epub ahead of print].

16. Zhou T, Benda C, Dunzinger S, Huang Y, Ho JC, et al. (2012) Generation of human induced pluripotent stem cells from urine samples. Nat Protocols 7: 2080–2089.

17. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, et al. (2009) Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences. Science 324: 97–100.

18. Chou B-K, Mali P, Huang X, Ye Z, Dower SN, et al. (2011) Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res 21: 518–529.

19. Mack AR, Kroboth S, Rajesh D, Wang WB (2011) Generation of Induced Pluripotent Stem Cells from CD34+ Cells across Blood Drawn from Multiple Donors with Non-Integrating Episomal Vectors. PLoS ONE 6: e27956.

20. Yu J, Chau K, Vodyanik MA, Jiang J, Jiang Y (2011) Efficient Feeder-Free Episomal Reprogramming with Small Molecules. PLoS ONE 6: e17557.

21. Ludwig TE, Levenstein ME, Jones JM, Berggren WT, Minchen ER, et al. (2006) Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol 24: 185–187.

22. Chen G, Gulbranson DR, Hou Z, Bolin JM, Ruotti V, et al. (2011) Chemically defined conditions for human iPSC derivation and culture. Nature Methods 8: 424–429.

23. Oikita K, Ichisaka T, Yamanaka S (2007) Generation of germ-line-competent induced pluripotent stem cells. Nature 448: 313–317.

24. Liao B, Yao L, Liu L, Feng S, Zouolii A, et al. (2011) MicroRNA Cluster 302–305 Enhances Somatic Cell Reprogramming by Accelerating a Mesenchymal-to-Epithelial Transition. J Biol Chem 286: 17339–17346.

25. Subramaniam D, Lamouille S, Judson RL, Liu JY, Bucy N, et al. (2011) Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat Biotechnol 29: 443–449.

26. Hu S, Wilson KD, Ghosh Z, Han L, Wang Y, et al. (2012) MicroRNA-302 Increases Reprogramming Efficiency via Repression of NR2F2. STEM CELLS 31: 259–268.

27. Liu N-L, Chang DC, Ying S-Y, Liu D, Wu DTS (2010) MicroRNA miR-302 Inhibits the Tumorigenicity of Human Pluripotent Stem Cells by Coordinate Suppression of the CDK2 and CDK4/6 Cell Cycle Pathways. Cancer Res 70: 9473–9482.

28. Li K, Liang J, Ni S, Zhou T, Qiong X, et al. (2010) A Mesenchymal-to-Epithelial Transition Initiates and Is Required for the Nuclear Reprogramming of Mouse Fibroblasts. Cell Stem Cell 7: 51–63.

29. Uitkahl J, Pole JM, Stadtfeld M, Maherali N, Kulartw W, et al. (2009) Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 460: 1149–1154.

30. Hanna J, Markouala S, Mitalka M, Cheng AW, Cassady JP, et al. (2009) Metastable Pluripotent States in NOD-Mouse-Derived ESCs. Cell Stem Cell 4: 513–524.

31. Gore A, Li Z, Fung H-L, Young JE, Agarwal S, et al. (2011) Somatic coding mutations in human induced pluripotent stem cells. Nature 471: 63–67.

32. Hussein SM, Batada NN, Vuoristo S, Ching RW, Auto R, et al. (2011) Copy number variation and selection during reprogramming to pluripotency. Nature 471: 50–62.

33. Martin-Taylor K, Niiler BS, Taapken SM, Compton T, Crandall L, et al. (2011) Recurrent copy number variations in human induced pluripotent stem cells. Nat Biotechnol 29: 448–491.

34. Cheng L, Hansen Nancy F, Zhao L, Bu Y, Zou C, et al. (2011) Low Incidence of DNA Sequence Variation in Human Induced Pluripotent Stem Cells Generated by Nonintegrating Plasmid Expression. Cell Stem Cell 10: 337–344.

35. Geti I, Ormiston ML, Roshani F, Toshner M, Mavasagh M, et al. (2012) A Practical and Efficient Cellular Substrate for the Generation of Induced Pluripotent Stem Cells from Adults: Blood-Derived Endothelial Progenitor Cells. Stem Cells Translational Medicine 1: 855–865.

36. Lefort N, Feyeux M, Bas C, Fe´raud O, Bennaceur-Griscelli A, et al. (2008) Human embryonic stem cells reveal recurrent genomic instability at 20q11.21. Nature Biotechnol 26: 1364–1366.

37. Wang L, Wang L, Huang W, Su H, Xue Y, et al. (2013) Generation of integration-free neural progenitor cells from cells in human urine. Nat Methods 10: 94–99.

38. Li W, Sun W, Zhang Y, Wei W, Ambasundhar RN, et al. (2011) Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors. Proc Natl Acad Sci U S A 108: 8299–8304.

39. Denham M, Bye C, Leung J, Conley BJ, Thompson LH, et al. (2012) Glycogen Synthase Kinase 3β and Activin/Nodal Inhibition in Human Embryonic Stem Cells Induces a Pre-Neuroepithelial State That Is Required for Specification to a Floor Plate Cell Lineage. STEM CELLS 30: 2400–2411.